Astral Codex Ten

Aduhelm

3 min read

Aduhelm

Article

Aduhelm is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between August 20, 2021 and August 14, 2025. The archive places it in contexts such as ""The true tragedy of Aduhelm will be that the Alzheimer’s Disease research space""; “Tl;DR : Aduhelm sucks”; “Anti-amyloid drugs (like Aduhelm ) don’t reverse the disease, and only slow progression a relatively small amount”. It most often appears alongside aducanumab, aducanumab, amyloid.

Metadata

  • Category: Brands
  • Mention count: 2
  • Issue count: 2
  • First seen: August 20, 2021
  • Last seen: August 14, 2025

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Highlights From The Comments On Aducanumab
August 20, 2021 · Original source
These are highlights from the comments of Adumbrations Of Aducanumab, Details Of The Infant Fish Oil Story, and discussion of those posts elsewhere.
Inline links: Adumbrations Of Aducanumab, Details Of The Infant Fish Oil Story
C_B writes:
Inline links: writes
I agree with this post's overall point that the FDA is not, on average, too lax, and that the Atlantic article's take that the aducanumab approval is a sign of them being too lax is a bad take.
In Defense Of The Amyloid Hypothesis
August 14, 2025 · Original source
Aducanumab in phase 1b [77] (19% on my average across cognitive endpoints for the highest two doses) and one of two phase 3 trials [78] (22%, but negative 2% in the other trial, which also gave a lower dose on average).
But biology is messy, and we need to have comfort with complexity. Yes, there’s evidence that tau is responsible for the neurodegeneration in Alzheimer’s disease; no, this doesn’t contradict the amyloid hypothesis. Yes, Biogen screwed up in conducting the aducanumab phase 3 trials and this made the results harder to interpret; no, that doesn’t mean amyloid therapies have completely failed. Yes, it’s taken way too long to get even to this intermediate point of 30% efficacy, due to a combination of overregulation and biology just being damned hard; no, that doesn’t mean we’re on the wrong track with the underlying science.
[77] J. Sevigny et al., “The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease,” Nature, vol. 537, no. 7618, pp. 50–56, Sep. 2016, doi: 10.1038/nature19323.
Inline links: 10.1038/nature19323